X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10103) 10103
Publication (737) 737
Newsletter (191) 191
Book Review (109) 109
Newspaper Article (40) 40
Book Chapter (21) 21
Conference Proceeding (8) 8
Transcript (6) 6
Dissertation (4) 4
Magazine Article (4) 4
Data Set (3) 3
Book / eBook (2) 2
Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7574) 7574
methotrexate (6251) 6251
female (4780) 4780
index medicus (4638) 4638
male (4506) 4506
middle aged (3349) 3349
adult (3040) 3040
methotrexate - therapeutic use (2869) 2869
rheumatology (2712) 2712
rheumatoid arthritis (2617) 2617
treatment outcome (2132) 2132
arthritis, rheumatoid - drug therapy (2123) 2123
aged (2081) 2081
immunology (2047) 2047
antirheumatic agents - therapeutic use (1689) 1689
methotrexate - administration & dosage (1505) 1505
oncology (1495) 1495
animals (1491) 1491
arthritis (1418) 1418
therapy (1417) 1417
adolescent (1326) 1326
hematology (1281) 1281
care and treatment (1216) 1216
drug therapy, combination (1188) 1188
child (1102) 1102
immunosuppressive agents - therapeutic use (1082) 1082
double-blind (1058) 1058
rheumatoid-arthritis (1047) 1047
rheumatoid factor (1001) 1001
drug therapy (989) 989
medicine & public health (985) 985
infliximab (972) 972
transplantation (936) 936
patients (906) 906
research (903) 903
methotrexate - adverse effects (901) 901
arthritis, rheumatoid - immunology (891) 891
chemotherapy (868) 868
disease (813) 813
analysis (809) 809
methotrexate - pharmacology (804) 804
cancer (802) 802
etanercept (787) 787
retrospective studies (780) 780
risk factors (774) 774
antibodies, monoclonal - therapeutic use (740) 740
tumor necrosis factor-alpha - antagonists & inhibitors (740) 740
child, preschool (713) 713
efficacy (684) 684
severity of illness index (676) 676
antirheumatic agents - adverse effects (665) 665
mice (664) 664
health aspects (651) 651
pharmacology & pharmacy (620) 620
children (614) 614
inflammation (610) 610
time factors (608) 608
medical research (580) 580
antineoplastic combined chemotherapy protocols - therapeutic use (579) 579
follow-up studies (570) 570
prognosis (561) 561
clinical trials (548) 548
dermatology (533) 533
young adult (533) 533
dosage and administration (517) 517
research article (511) 511
safety (511) 511
cyclosporine (503) 503
psoriasis (496) 496
trial (492) 492
antirheumatic agents - administration & dosage (490) 490
remission (481) 481
prospective studies (477) 477
diagnosis (474) 474
dose-response relationship, drug (474) 474
adalimumab (473) 473
leukemia (469) 469
remission induction (468) 468
graft vs host disease - prevention & control (459) 459
pediatrics (450) 450
medicine, experimental (443) 443
transplantation, homologous (443) 443
abridged index medicus (428) 428
aged, 80 and over (428) 428
expression (425) 425
cyclophosphamide (417) 417
rituximab (414) 414
cytokines (410) 410
medicine (408) 408
cyclophosphamide - therapeutic use (401) 401
risk (400) 400
corticosteroids (394) 394
monoclonal-antibody (390) 390
tumor necrosis factor (386) 386
drugs (384) 384
infant (383) 383
drug administration schedule (382) 382
immunosuppressive agents - adverse effects (382) 382
monoclonal antibodies (379) 379
studies (379) 379
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10029) 10029
German (105) 105
Japanese (61) 61
French (50) 50
Russian (45) 45
Chinese (29) 29
Italian (23) 23
Spanish (21) 21
Polish (13) 13
Hungarian (12) 12
Dutch (5) 5
Korean (4) 4
Portuguese (4) 4
Danish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Swedish (2) 2
Czech (1) 1
Finnish (1) 1
Icelandic (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Immunology, ISSN 0022-1767, 05/2005, Volume 174, Issue 9, pp. 5789 - 5795
The adipokine resistin is suggested to be an important link between obesity and insulin resistance. In the present study, we assessed the impact of resistin as... 
RHEUMATOID-ARTHRITIS | TRIAL | IN-VITRO | PROTEIN | CONCOMITANT METHOTREXATE | INSULIN-RESISTANCE | GENE-EXPRESSION | MONOCLONAL-ANTIBODY | IMMUNOLOGY | ANTITUMOR NECROSIS FACTOR | FACTOR-ALPHA | Hormones, Ectopic - administration & dosage | Inflammation Mediators - administration & dosage | Interleukin-1 - genetics | Intracellular Fluid - immunology | Humans | Middle Aged | Tumor Necrosis Factor-alpha - genetics | Synovial Membrane - immunology | Synovial Membrane - pathology | Male | NF-kappa B - metabolism | Arthritis, Experimental - metabolism | Interleukin-1 - biosynthesis | Arthritis, Experimental - pathology | Arthritis, Rheumatoid - metabolism | Signal Transduction - immunology | Aged, 80 and over | Adult | Female | Inflammation Mediators - physiology | Adipocytes - immunology | Intracellular Fluid - metabolism | Resistin | Interleukin-6 - genetics | Cells, Cultured | Arthritis, Experimental - immunology | Hormones, Ectopic - physiology | Recombinant Proteins - pharmacology | Synovial Membrane - metabolism | Recombinant Proteins - administration & dosage | Arthritis, Rheumatoid - pathology | Animals | Adipocytes - metabolism | Adolescent | Injections, Intra-Articular | NF-kappa B - physiology | Interleukin-6 - biosynthesis | Aged | Mice | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Recombinant Proteins/administration & dosage/pharmacology | Intracellular Fluid/immunology/metabolism | Arthritis | MEDICIN OCH HÄLSOVETENSKAP | Hormones | Experimental/immunology/metabolism/pathology | Inflammation Mediators/administration & dosage/physiology | 80 and over | Interleukin-6/biosynthesis/genetics | Tumor Necrosis Factor-alpha/biosynthesis/genetics | Ectopic/administration & dosage/physiology | Cultured | Adipocytes/immunology/metabolism | Interleukin-1/biosynthesis/genetics | Rheumatoid/immunology/metabolism/pathology | MEDICAL AND HEALTH SCIENCES | Synovial Membrane/immunology/metabolism/pathology | Cells | Intra-Articular | NF-kappa B/metabolism/physiology | Injections | Signal Transduction/immunology
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 02/2014, Volume 170, Issue 2, pp. 261 - 273
Journal Article
Journal Article
Journal of Immunology, ISSN 0022-1767, 03/2018, Volume 200, Issue 6, pp. 2038 - 2045
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 12/2011, Volume 13, Issue 6, pp. R209 - R209
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 03/2005, Volume 64, Issue 3, pp. 403 - 407
Background: Research on autoantibody formation in patients treated with TNFα inhibitors has produced contradictory results. Objective: To study the prevalence... 
APOPTOSIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | ETANERCEPT THERAPY | CROHNS-DISEASE | METHOTREXATE | INFLIXIMAB TREATMENT | NECROSIS-FACTOR-ALPHA | MONOCLONAL-ANTIBODY | INDUCTION | RHEUMATOLOGY | T-CELLS | Drug Hypersensitivity - etiology | Antibodies, Antinuclear - biosynthesis | DNA - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antirheumatic Agents - immunology | Antibodies, Monoclonal - therapeutic use | Male | Autoantibodies - biosynthesis | Immunoglobulin G - biosynthesis | Infliximab | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Adult | Female | Aged | Arthritis, Rheumatoid - immunology | Drug Therapy, Combination | Antibodies, Monoclonal - immunology | Antirheumatic Agents - therapeutic use | Immunoglobulin M - biosynthesis | Etanercept | Drug therapy | Rheumatoid arthritis | Patient outcomes | Extended Report | Clinical immunology | Mikrobiologi, immunologi, infektionssjukdomar | Medical and Health Sciences | Autoantibodies/biosynthesis | Medicin och hälsovetenskap | Reumatologi och inflammation | Antibodies; Antinuclear/biosynthesis | Immunologi inom det medicinska området | Klinisk medicin | MEDICINE | Rheumatology and Autoimmunity | Immunology | Antirheumatic Agents/adverse effects/immunology/therapeutic use | DNA/immunology | Antibodies; Monoclonal/adverse effects/immunology/therapeutic use | Drug Therapy; Combination | Klinisk immunologi | Invärtesmedicin | Dermatologi och venerologi, klinisk genetik, invärtesmedicin | Immunology in the medical area | Basic Medicine | Immunoglobulin G/biosynthesis | Immunologi | Internal medicine | Arthritis; Rheumatoid/drug therapy/immunology | Rheumatology | Reumatologi | Immunoglobulin M/biosynthesis | Dermatology and venerology,clinical genetics, internal medicine | Clinical Medicine | Drug Hypersensitivity/etiology | Microbiology, immunology, infectious diseases | MEDICIN | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 12/2013, Volume 72, Issue 12, pp. 1947 - 1955
Background Immunogenicity of aTNFs is one of the mechanisms behind treatment failure. Objective To assess the effect of anti-drug antibodies (ADA) on drug... 
ALPHA MONOCLONAL-ANTIBODY | CONCOMITANT METHOTREXATE | CROHNS-DISEASE | Anti-TNF | ANKYLOSING-SPONDYLITIS | RHEUMATOLOGY | ANTITUMOR NECROSIS FACTOR | RHEUMATOID-ARTHRITIS PATIENTS | Autoimmune Diseases | ADALIMUMAB ANTIBODIES | EPISODIC TREATMENT | Methotrexate | LONG-TERM TREATMENT | CLINICAL-RESPONSE | Inflammatory Bowel Diseases - drug therapy | Methotrexate - pharmacology | Evidence-Based Medicine - methods | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Inflammatory Bowel Diseases - immunology | Antirheumatic Agents - immunology | Autoimmune Diseases - immunology | Anti-Inflammatory Agents, Non-Steroidal - immunology | Antibodies, Monoclonal - therapeutic use | Infliximab | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antibody Formation - drug effects | Arthritis - drug therapy | Arthritis - immunology | Adalimumab | Antibodies, Monoclonal, Humanized - immunology | Immunosuppressive Agents - pharmacology | Antibodies, Monoclonal - immunology | Autoimmune Diseases - drug therapy | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Immunogenetics | Usage | Biological products | Tumor necrosis factor inhibitors | Influence | Research | Health aspects | Meta-analysis | Immunoglobulins | Clinical trials | Patients | Crohns disease | Studies | Inflammatory bowel disease | Immunotherapy | Measurement techniques | Tumor necrosis factor-TNF | Clinical medicine | Drug dosages
Journal Article
Journal Article
by Herrick, Ariane L and Pan, Xiaoyan and Peytrignet, Sébastien and Lunt, Mark and Hesselstrand, Roger and Mouthon, Luc and Silman, Alan and Brown, Edith and Czirják, László and Distler, Jörg H W and Distler, Oliver and Fligelstone, Kim and Gregory, William J and Ochiel, Rachel and Vonk, Madelon and Ancuţa, Codrina and Ong, Voon H and Farge, Dominique and Hudson, Marie and Matucci-Cerinic, Marco and Balbir-Gurman, Alexandra and Midtvedt, Øyvind and Jordan, Alison C and Jobanputra, Paresh and Stevens, Wendy and Moinzadeh, Pia and Hall, Frances C and Agard, Christian and Anderson, Marina E and Diot, Elisabeth and Madhok, Rajan and Akil, Mohammed and Buch, Maya H and Chung, Lorinda and Damjanov, Nemanja and Gunawardena, Harsha and Lanyon, Peter and Ahmad, Yasmeen and Chakravarty, Kuntal and Jacobsen, Søren and MacGregor, Alexander J and McHugh, Neil and Müller-Ladner, Ulf and Riemekasten, Gabriela and Becker, Michael and Roddy, Janet and Carreira, Patricia E and Fauchais, Anne Laure and Hachulla, Eric and Hamilton, Jennifer and İnanç, Murat and McLaren, John S and van Laar, Jacob M and Pathare, Sanjay and Proudman, Susannah and Rudin, Anna and Sahhar, Joanne and Coppere, Brigitte and Serratrice, Christine and Sheeran, Tom and Veale, Douglas J and Grange, Claire and Trad, Georges-Selim and Denton, Christopher P and Sahlgrenska akademin and Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning and Institute of Medicine, Department of Rheumatology and Inflammation Research and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Annals of the Rheumatic Diseases, ISSN 0003-4967, 07/2017, Volume 76, Issue 7, pp. 1207 - 1218
ObjectivesThe rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational... 
Systemic Sclerosis | Cyclophosphamide | Treatment | Methotrexate | CONTROLLED-TRIAL | PLACEBO | METAANALYSIS | PROPENSITY SCORE | CYCLOPHOSPHAMIDE | CLINICAL-TRIALS | MARGINAL STRUCTURAL MODELS | SKIN THICKNESS SCORE | LUNG-DISEASE | RHEUMATOLOGY | HEALTH-ASSESSMENT QUESTIONNAIRE | Severity of Illness Index | Prospective Studies | Antibodies, Antinuclear - immunology | Europe | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Survival Rate | Treatment Outcome | Methotrexate - therapeutic use | Nuclear Proteins - immunology | RNA Polymerase III - immunology | Cyclophosphamide - therapeutic use | Autoantibodies - immunology | Mycophenolic Acid - therapeutic use | Early Medical Intervention | Adult | Female | Scleroderma, Diffuse - drug therapy | Cohort Studies | Scleroderma, Diffuse - immunology | Treatment outcome | Care and treatment | Systemic scleroderma | Analysis | Scleroderma (Disease) | Mycophenolic acid | Statistical analysis | Mortality | Lung diseases | Clinical trials | Arthritis | Survival | Patients | Immunosuppressive agents | Quality of life | Variables | Systemic sclerosis | Questionnaires | Stem cells | Skin | Clinical medicine | Mycophenolate mofetil | Scleroderma | Health risk assessment | Drug dosages | Chronic illnesses | Clinical and Epidemiological Research | 1506 | Rheumatology and Autoimmunity | Reumatologi och inflammation
Journal Article